Mike Cooke

CEO

Mike Cooke picture

Mike Cooke

AmacaThera

CEO

Dr. Cooke completed his PhD in stem cell biology at the University of Durham (UK), where he studied controlling cell fate methods. During his post-doctoral work, Dr. Cooke investigated combining a hydrogel (HAMC) with neural stem/progenitor cells to repair the stroke injured mouse brain. He successfully demonstrated that cells combined with HAMC could lead to functional recovery of the stroke injured mouse brain. More recently, Dr. Cooke has co-founded AmacaThera Inc. with Prof Molly Shoichet to commercialize novel hydrogels. The lead product is focused on improving post-operative pain management and has applicability to any surgical incision. Dr. Cooke is AmacaThera’s CEO and, in 18 months, has guided the AmacaThera team to successfully gain approval from Health Canada to initiate a Phase 1 clinical trial. AmacaThera recently closed an oversubscribed CDN$10.3 Series A Venture Capital financing to further the clinical development and expand uses of the drug delivery platform.